Clinical trials: Metastatic Colorectal Cancer (mCRC)
Colorectal Neoplasms
Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC
To evaluate the clinical efficacy and safety of hypofractionation radiotherapy combined with sintilimab，GM-CSF and Fruquintinib in Patients With MSS Metastatic Colorectal Carcinoma (mCRC)
- Trial name
- NCT05292417
- Testing
- hypofractionation Radiotherapy, sintilimab, GM-CSF
- Where
- China
- Volunteers
- 71 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Metastatic Colorectal Cancer (mCRC)
Emulation of the SUNLIGHT Trial Using Specialty Oncology Electronic Health Records Databases
This observational study uses existing U.S. specialty oncology electronic health records to emulate the SUNLIGHT trial. It compares survival among adults with metastatic colorectal cancer who began trifluridine-tipiracil plus…
- Trial name
- NCT07861360
- Testing
- Initiation of trifluridine-tipiracil plus bevacizumab, Initiation of trifluridine-tipiracil alone
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Brigham and Women's Hospital
Carcinoma, Hepatocellular, Metastatic Colorectal Cancer
Vandetanib-eluting Radiopaque Embolic Beads in Patients With Resectable Liver Malignancies
This is a pilot, open label single arm phase 0 window of opportunity study of vandetanib-eluting radiopaque beads in patients with resectable liver malignancies.
- Trial name
- VEROnA (NCT03291379)
- Testing
- BTG-002814
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- Boston Scientific Corporation
Colorectal Cancer Metastatic
Evaluation of CTCs Combined With Tumor Marker Detection of Efficacy of Chemotherapy in mCRC
Evaluation of individual peripheral blood circulating tumor cells combined with tumor marker detection of efficacy of chemotherapy in patients with advanced colorectal cancer: A observational clinical trial
- Trial name
- NCT02948985
- Testing
- treated with FOLFIRI±cetuximab
- Volunteers
- 100 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Metastatic Colorectal Cancer
TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated mCRC
Primary Objective: To determine disease control rate (DCR) of TS-1® in patients with heavily pre-treated metastatic colorectal cancer Secondary Objectives: To determine objective response rate (ORR) To determine time to…
- Trial name
- NCT03517618
- Testing
- S-1+leucovorin
- Where
- Taiwan
- Volunteers
- 41 people
- Sponsor
- TTY Biopharm
Metastatic Colorectal Adenocarcinoma
Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC
Fruquintinib with PD-1 inhibitors (FP) and TAS-102 with bevacizumab (TB) are two common therapies for patients with previous-treated metastatic colorectal cancer (mCRC).
- Trial name
- NCT06031376
- Testing
- Fruquintinib, PD-1 inhibitors, Trifluridine/Tipiracil
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Hunan Cancer Hospital
Metastatic Colorectal Cancer
A Study of Fruquintinib in Adults With Metastatic Colorectal Cancer in Poland
Metastatic colorectal cancer or mCRC is a cancer that starts in the parts of the large intestine (the colon or rectum) and has already spread to other parts of the body.
- Trial name
- NCT07623174
- Testing
- No intervention
- Where
- 10 sites in Poland
- Volunteers
- 110 people
- Sponsor
- Takeda
Advanced Colorectal Cancer
Effect of Curcumin on Dose Limiting Toxicity and Pharmacokinetics of Irinotecan in Patients With Solid Tumors
Curcumin is an extract of the tumeric root that has been shown to have anti-tumor properties in laboratory studies. Curcumin, and its parent spice, turmeric (curcuma longa), are the 4th most commonly purchased dietary supplement…
- Trial name
- NCT01859858
- Testing
- curcumin, Irinotecan
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Colorectal Cancer Metastatic
Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC
Patient with multiple metastases, not eligible for surgery, might not profit from intensive chemotherapy regimens. Therefore less intensive regimens focusing on survival and disease control may be a better choice for first line…
- Trial name
- NCT01249638
- Testing
- Capecitabine, Bevacizumab, Irinotecan
- Where
- Germany
- Volunteers
- 516 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Metastatic Colorectal Cancer
Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC
A randomized phase II trial of FOLFOXIRI in Combination With GM-CSF and IL-2 (FOLFOXIGIL) Versus FOLFOXIRI as First-line Treatment for Patients With Metastatic Colorectal Cancer.
- Trial name
- NCT03222089
- Testing
- Irinotecan, Oxaliplatin, Levoleucovorin
- Where
- China
- Sponsor
- Fujian Cancer Hospital
Metastatic Colorectal Cancer (CRC)
ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer
HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells.
- Trial name
- NCT06825624
- Testing
- HS-20093, Bevacizumab, 5-FU
- Where
- China
- Volunteers
- 560 people
- Sponsor
- Hansoh BioMedical R&D Company
Metastatic Colorectal Cancer
Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects
To determine if sorafenib when added to chemotherapy will slow disease progression more than chemotherapy alone in patients previously untreated for metastatic colorectal cancer.
- Trial name
- NCT00865709
- Testing
- Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)
- Where
- 116 sites in United States, Belgium and 8 more
- Volunteers
- 198 people
- Sponsor
- Bayer
Metastatic Colorectal Cancer
Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)
The goals of this clinical study are to learn more about the safety, tolerability and effectiveness of magrolimab in combination with bevacizumab and 5-fluorouracil, irinotecan, and leucovorin (FOLFIRI) in previously treated…
- Trial name
- ELEVATE CRC (NCT05330429)
- Testing
- Magrolimab, Bevacizumab, Irinotecan
- Where
- 51 sites in United States, Australia and 8 more
- Volunteers
- 77 people
- Sponsor
- Gilead Sciences
Progression-Free Survival
Metformin for the Treatment of mCRC Patients Undergoing FOLFIRI Plus Target Therapy
To investigate progression-free survival (PFS) in patients with metastatic colorectal cancer treated with chemotherapy FOLFIRI monotherapy or chemotherapy FOLFIRI combined with Metformin
- Trial name
- NCT06826092
- Testing
- Metformin Pill, FOLFIRI plus target therapy only
- Where
- Taiwan
- Volunteers
- 110 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Metastatic Colorectal Cancer (mCRC)
CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen
This is an open label, randomized, two arm, multi-center study to explore the effect of leronlimab on the overall response rate/ overall survival and safety and tolerability when used in combination with trifluridine and…
- Trial name
- CLOVER (NCT06699836)
- Testing
- 350 mg leronlimab, 700 mg leronlimab, 200 mg pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 66 people
- Sponsor
- CytoDyn, Inc.
Metastatic Colorectal Cancer, Colorectal Cancer
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
The purpose of this study is to evaluate whether therapy with MORAb-004 is effective and safe in the treatment of metastatic, colorectal cancer.
- Trial name
- NCT01507545
- Testing
- MORAb-004, Best supportive care
- Where
- 67 sites in United States
- Volunteers
- 154 people
- Sponsor
- Morphotek
Metastatic Colorectal Cancer
Metastatic Colorectal Cancer. Real-World Data Analysis.
The Treatment Choices, Duration and Outcomes in Patients with Ras Wild Type (RAS WT) Metastatic Colorectal Cancer (mCRC). Retrospective, Multi-Center, Real-World Data Analysis
- Trial name
- RWD-mCRC-001 (NCT04757311)
- Where
- Turkey (Türkiye)
- Volunteers
- 1,750 people
- Sponsor
- Istanbul Medeniyet University
Colorectal Cancer
Efficacy and Safety of Regorafenib Maintenance Therapy in Patients With Metastatic Colorectal Cancer (mCRC)
Regorafenib in third-line treatment of metastatic colorectal cancer(mCRC) significantly prolongs the survival of patients, and its advancement has a sensitizing effect on postline chemotherapy and thus improves the prognosis of…
- Trial name
- NCT05818267
- Testing
- Regorafenib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Wei Zhang
Colorectal Cancer
Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC
The purpose of this study is to verify the efficacy of mFOLFOX6 + panitumumab combination therapy and mFOLFOX6 + bevacizumab combination therapy in first-line treatment of chemotherapy-naive patients with KRAS/NRAS wild-type…
- Trial name
- PARADIGM (NCT02394795)
- Testing
- oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab, oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab
- Where
- 155 sites in Japan
- Volunteers
- 823 people
- Sponsor
- Takeda
Intestinal Neoplasms, Gastrointestinal Neoplasms
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)).
- Conditions
- Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site
- Trial name
- NCT07222800
- Testing
- PF-08634404, Bevacizumab, Chemotherapy
- Where
- 372 sites in United States, Argentina and 15 more
- Volunteers
- 800 people
- Sponsor
- Pfizer